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with possible TF approach was substantially higher (70.2%). In the remaining 29.8%
not treatable using this AW, 48.4% fulfilled the anatomical criteria regarding the SA.
In summary, 84.6% of patients provide suitable AW for “conventional” TAVI with the
MCV.
Conclusion: The majority of patients with AVS scheduled for TAVI show sufficient
AW for “conventional” TAVI with the MCV. Anyhow, a substantial number of patients
are not eligible due to inappropriate AW. Consecutively, the retrograde trans-aortic
AW, which is rarely performed, may be an option to solve this problem.
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Background: Minimally-invasive and transcatheter approaches have become very
popular particularly for aortic valve procedures. While the former continues to improve
the operative technique, the application of catheter-delivery technologies in selected
high risk patients is becoming more and more challenging. This is more specifically
true for patients with mitral regurgitation who present a burgeoning clinical unmet
need for therapeutic advances and a transcatheter implanted mitral valve may offer a
very effective treatment alternative and this begins with the sutureless implantation of
such device.
Methods: This study describes the initial results of the feasibility study of the sutureless
implantation of mitral valve prostheses in an acute ovine model. The device consists
of a pericardial bioprosthetic valve mounted within a expandable support structure.
The device is collapsed radially and balloon expanded radially, thereby providing a
secure attachment to the valve annulus without requiring sutures. The new stent-valve
was designed for a prospective catheter delivered implantation technique. The stent-
valves were deployed in the mitral annular position, through a left thoracotomy access,
cardiopulmonary bypass (CPB) institution and direct valve implantation in a beating
heart.
Results: All valves were successfully implanted. Echocardiographic assessment
confirmed excellent function of the bioprosthetic mitral valve with accurate positioning
and secure anchoring of the stent-valve onto the mitral annulus. Even at the highest
registered systolic AoP (>200 mmHg) with its attendant extreme dP/dt, there was no
dislocation of any part or the valve. No perivalvular leak or central mitral regurgitation
was observed. Confirmation of a clear unobstructed LVOT with preservation of the
subvalvular apparatus. Valve function evidenced normal hemodynamic performance
and pressure gradient across the implanted valve.
Conclusion: The new design of a contractible and expandable mitral valve prosthesis
demonstrated reliable valve performance, secure engagement of the native annulus
confirms the feasibility and suggests potential ease of implantation. Further chronic
study is needed to verify these results and evaluate reliability of implantation
procedures, biocompatibility, and valve durability. This signals that transition to a
transcatheter valve delivery may be eased by the attributes of this new device.
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Background: Transcatheter aortic valve implantation (TAVI) is performed via the
trans-femoral (TF) route as the first choice delivery approach with encouraging results
from worldwide registries. Vascular access management is a major challenge in TF
TAVI due to the need for large-sized introducer sheaths. Bleedings are common
complications of the TAVI procedure are related to sheath size. The new generations
of TAVI systems are significatively smaller than the first generation systems.In this
study we report the incidence of bleedings in patients undergoing TAVI in a single
centre institution.
Methods: From June 2008 to May 2011, a total of 156 patients in our institutions
underwent TAVI using the TF approach. Patients were divided into two groups
according to the TAVI system adopted: Group A (Retroflex, Edwards Life Sciences)
and Group B (Novaflex, Edwards Life Sciences). Patients received a detailed clinical
assessment and serial blood testing before and one hour, twenty four hours and at
discharge after TAVI. At one month patients underwent a clinical follow up visit.
Bleedings and vascular complications were classified according to the VARC criteria.
Results: At 30 days the incidence of mayor and minor vascular complications was
significatively lower in group B (p<0.05). No distal embolizations occurred in any of
the groups. The reduced incidence of vascular complications was associated with a
reduced incidence of Life-Threatening Bleedings, Mayor Bleedings and Minor
bleedings were significatively, in group B (p<0.05). Overall this resulted into a
significative reduction in 30 days mortality (7.7 % vs 1.6%, (p<0.05) and in particular
annealed the occurrence of vascular related.
Conclusion: The use of the Novaflex system allowed a reduction of post TAVI
bleedings, vascular complications, vascular related deaths and 30 mortality. This data,
if confirmed in a large metacentre registry, would further support the diffusion of TAVI
for the treatment of patients with severe aortic stenosis and at high surgical risk.
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Background: Neurologic impairment post AVR correlates with Transcranial Doppler
(TCD)-measured embolic high intensity signals (HITS), but less is known about their
occurrence in the transcatheter-based aortic valve insertion (TAVI) procedures where
risk for stroke is reported to be higher. This study compares HITS across common
events during TF-transfemoral and TA-transapical TAVI.
Methods: Output from TCD provided time-stamped HITS detection and artifacts
rejection. Procedural events were marked throughout TAVI-TF (n=21) and TAVI-TA
(n=21). HITS during BAV- and Valve- delivery System Intervals (B-SI and V-SI) were
then compared. Balloon delivery system (TF) or apical sheath insertion (TA) marked
B-SI start. VS-I was initiated (and B-SI ended) with insertion of the valve delivery
system (into the arch for TF and into the apex for TA). VS-I ended when 60 seconds
had passed following valve delivery system removal (TF) or apical sheath removal
(TA). Specific events within each interval were also compared, with HITS counted for
60sec following each.
Results: Though not significant (p=0.1), total HITS were greater in TAVI-TF (674)
than TA (542). In both procedures, V-SI created more emboli than B-SI (p<0.001).
Subdivision of the events during VS-I revealed a larger number of HITS during valve
deployment in TF than TA (p< .01). Advancement of the valve across the aortic arch
(unique to TF) also contributed. B-SI HITS were highest during TA insertion of the
apical sheath.
Conclusion: Patients are at more risk for embolic events during valve deployment than
during BAV. TAVI procedures may benefit from an intravascular filter prior to delivery
across the aortic arch in TF and placement prior to apical sheath insertion in TA.
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Background: To evaluate the feasibility, safety and valve performance of the
JenaValveTM for transapical transcatheter aortic valve implantation (TAVI) during the
first-in-man (FIM) study.
Methods: The JenaValveTM aortic valve replacement (AVR) TAVI System is composed
of a porcine xenograft attached on a self-expandable Nitinol stent. It allows precise
anatomical valve orientation by three positioning arms. The stent design anchoring the
native leaflets, the sub-coronary position and the possibility of retrieving the valve
before final release provide potential advantages compared to current TAVI systems.
Between 07/09 and 04/2010 twelve patients were enrolled. Mean age was 85.9±4.0
years, all patients were female, log EuroSCORE was 24.7±10.5% and STS score was
10.3±4.3. Native annulus size was 21.4±1.2mm. The procedure was aborted in one
patient due to acute type A dissection and in two patients because the positioning arms
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